Cardiac dysfunction in type II diabetes: a bittersweet, weighty problem, or both? by Melissa Leung et al.
ORIGINAL ARTICLE
Cardiac dysfunction in type II diabetes: a bittersweet, weighty
problem, or both?
Melissa Leung1,2,3 • Vincent W. Wong2,4 • Ertugrul Durmush5 • Victoria Phan1,2 •
Mikey Xie1,2 • Dominic Y. Leung1,2
Received: 23 June 2016 / Accepted: 1 September 2016 / Published online: 1 October 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Aims Weight loss in obese patients leads to improved left
ventricular (LV) function. It is unclear whether improving
glycaemic control has additional benefits to weight loss
alone in patients with type 2 diabetes, or if benefits of
weight loss are mediated through improving glycaemic
control. This case–control study examined the incremental
impact of these approaches on LV function.
Methods Three groups of age, gender, and baseline
HbA1c-matched patients with type 2 diabetes and subop-
timal glycaemic control were followed-up for 12 months.
Group 1 patients did not improve HbA1c C 1 %
(10.9 mmol/mol) or lose weight. Group 2 improved
HbA1c C 1 % but did not lose weight. Group 3 improved
HbA1c C 1 % (10.9 mmol/mol) and lost weight. All
patients underwent transthoracic echocardiogram at base-
line and at follow-up.
Results At baseline, three groups were comparable in all
clinical and metabolic parameters except Group 3 had
highest body mass index. The three groups had similar
echocardiographic parameters except Group 3 had the
worst LV systolic function [global longitudinal strain
(GLS)]. At follow-up, LV ejection fraction and diastolic
function improved with a reduction in filling pressures in
Group 2 and more so in Group 3. LV filling pressures in
Group 1 increased. There was a significant improvement in
GLS in Group 2 and more so in Group 3. Despite GLS
being the worst in Group 3 at baseline, this was comparable
between Groups 2 and 3 at follow-up.
Conclusions In overweight patients with type 2 diabetes,
weight loss and improved glycaemic control had additive
beneficial effects on improving LV systolic and diastolic
function.
Keywords Diabetic cardiomyopathy  Glycaemic control 
Left ventricular function  Echocardiography  Strain 
Weight loss  Bariatric surgery
Introduction
Patients with type 2 diabetes are often overweight and have
multiple vascular risk factors. This may manifest as left
ventricular (LV) systolic and/or diastolic dysfunction, or
blunted heart rate variability, not attributable to hyperten-
sion or myocardial ischaemia [1–5]. The underlying
pathophysiologic mechanisms of LV dysfunction in these
patients are multifactorial, but hyperglycaemia is consid-
ered a main determinant [6, 7]. However, the relationship
between glycaemic control and cardiac function has been
conflicting with some studies showing poor glycaemic
control was associated with abnormal LV relaxation,
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elevated LV filling pressures, and lower systolic strain
[2, 8, 9], while other studies demonstrated no such signif-
icant association [10–14]. Furthermore, studies examining
the relationship between glycaemic lowering and LV
function also gave inconsistent results [15–18].
Echocardiographic strain imaging and tissue Doppler
velocities are proven techniques in the assessment of LV
systolic and diastolic function that have incremental
prognostic value to traditional echocardiographic parame-
ters like LV ejection fraction [19–22]. Echocardiography-
based calibrated integrated backscatter (cIB), shown to be
related to histologically quantified collagen accumulation,
may be used as a measure of myocardial interstitial fibrosis
[23, 24].
Obesity alone, in the absence of diabetes, has also been
linked to LV dysfunction, and weight loss in obese patients
has been shown to result in improved LV function [25]. To
date, studies examining the relationship between glycaemic
lowering and LV function in patients with type 2 diabetes
have not clarified the differential impact of weight loss and
improved glycaemic control in overweight patients with
type 2 diabetes. It is unclear whether weight loss has
incremental benefits to improved glycaemic control in
these patients or indeed whether the benefits of weight loss
in obese patients with type 2 diabetes are mediated through
improved glycaemic control only. This case control study
was conducted to examine the differential and incremental
benefits of weight loss and improved glycaemic control on
LV function in obese patients with type 2 diabetes.
Subjects, materials, and methods
Patients
The study patients were recruited from a cardio-dia-
betology clinic where patients with poorly controlled
type 2 diabetes were referred and jointly managed by an
endocrinologist and a cardiologist. Eligible patients
included adults with type 2 diabetes with suboptimal
glycaemic control (glycated haemoglobin [HbA1c]
HbA1c C 7.0 %, 53 mmol/mol). Patients with type 1
diabetes, known congenital, valvular, or coronary artery
disease (CAD), severe hypertension ([200/120 mmHg at
rest), left bundle branch block, rhythm other than sinus,
previous or current treatment with thiazolidinediones,
and previous history of hypoglycaemia unawareness,
were excluded. All patients had significant CAD exclu-
ded by exercise echocardiography when they first
attended the clinic. Their glycaemic control, blood
pressure, and lipid profile were optimized, and they were
reviewed 3 monthly for 12 months after which time the
patients were discharged back to their primary care
physicians. Patients were advised to follow a diet of low
glycaemic index and to reduce excessive carbohydrate
and fat intake. Overweight or obese patients were rec-
ommended a healthy balanced diet but aimed at reduced
energy intake and referred for individual dietitian con-
sultation when necessary. Ten patients elected to
undergo bariatric surgery of their own volition and were
deemed suitable by a bariatric surgeon for laparoscopic
sleeve gastrectomy. These patients undertook a pre-op-
erative very low calorie diet in combination with a
3-week exercise programme supervised by an exercise
physiologist, a dietician, and a psychologist; following
which surgery was performed. All subjects had normal
resting electrocardiogram and provided written informed
consent. The study was approved by the Hospital Human
Ethics Committee.
A group of 20 patients (‘‘Group 1’’) who failed to
improve (or had worsened) their glycaemic control and
did not lose any weight after 12 months was identified.
Failure to improve glycaemic control was defined as an
improvement of HbA1c of B 1 % (10.9 mmol/mol) or
any increase in HbA1c after 12 months. A second group
(‘‘Group 2’’) of 20 age-, gender-, and baseline HbA1c-
matched patients who improved their glycaemic control
but did not lose any weight in the 12-month period was
selected. The third group (‘‘Group 3’’) of ten similarly
matched patients at study entry comprised those patients
who underwent sleeve gastrectomy, improved their gly-
caemic control [defined as a decrease of HbA1c[ 1 %
(10.9 mmol/mol) at 12 months] and who had lost weight
over the 12-month period. Therefore, the total study
population comprised of 50 patients.
Baseline clinical and metabolic data
Clinical data collected at baseline included age, height,
weight, waist and hip circumference, cardiac risk factors,
duration of diabetes, medications, and presence of
macrovascular and microvascular complications. All sub-
jects ranked their degree of breathlessness from 1 to 5
using the Medical Research Council (MRC) dyspnea scale
[26]. Those ranked scale 1 had minimal dyspnea except on
strenuous exercise, while those in scale 5 were too
breathlessness to perform simple tasks such as undressing.
Patients’ haemoglobin, HbA1c, serum creatinine, esti-
mated glomerular filtration rate (eGFR) using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula [27], fasting total cholesterol, low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides, C-reactive protein
(CRP), and urinary spot albumin-to-creatinine ratio were
measured at baseline and 12 months.
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Follow-up
All patients were reviewed 3 monthly at the clinic and had
their medical treatment for diabetes, blood pressure, and
cholesterol levels optimized aiming to achieve guideline-
recommended targets. Treatment was maintained and
monitored for 12 months.
Echocardiography protocols
All patients underwent rest echocardiography followed by
symptom-limited exercise echocardiography at baseline. A
repeat echocardiogram was performed at 12 months.
Two-dimensional and Doppler echocardiography
All transthoracic echocardiograms were performed with
Vivid E9, GE Medical Systems. All standard echo and
Doppler parameters of LV systolic and diastolic function
including pulse wave tissue Doppler were measured.
Left ventricular strain imaging
Globalmeanpeak longitudinal strain (GLS)andstrain rateof the
left ventricle was obtained with two-dimensional speckle
tracking analyses in apical 4-, 2-chamber and long-axis views
using highest possible frame rates. Analyses were performed by
experienced observers blinded to the clinical history and meta-
bolic profiles. The GLS and strain rate were calculated from the
three global longitudinal strain curves of the three apical views.
All Doppler and 2D speckle tracking echocardiographic mea-
surementswere taken as averages of three representative cycles.
Left atrial volume and function assessment
Left atrial (LA) volumes were measured from the apical
views according to the biplane Simpson’s method. The
following indices of LA function were measured: LA
reservoir volume was calculated as the difference between
the maximum and minimum LA volumes. Passive LA
emptying volume was calculated as the difference between
maximal and pre-contraction LA volumes. Active LA
emptying volume was calculated as the difference between
pre-contraction and minimum LA volumes. All LA vol-
umes were indexed to body surface area.
Calibrated integrated backscatter
The cIB curves were extracted in the parasternal long-axis
view, using standard software (Echopac, GE Vingmed).
Measurements were obtained by placing a 8 9 8 mm
region of interest in the subendocardial basal anteroseptum,
posterior wall, and pericardium at the peak of the R-wave
on the ECG in the parasternal long-axis view. cIB was
obtained by subtracting average pericardial backscatter
intensity from average myocardial backscatter intensity of
the anteroseptum or posterior wall.
Statistical analysis
A linear mixed model was used to assess the differences in
change in LA and LV dimensions and function over the
follow-up period between the three groups as it accounts
for the correlation of repeated measurements over time
within patients. The group (1, 2, or 3) and timing of
echocardiogram (baseline or 1 year) were incorporated in
the model as fixed variables in addition to the interaction
between the group and timing of echocardiogram.
Restricted maximum likelihood estimation with an
unstructured covariance matrix and a random intercept
model was used. The estimated marginal means and 95 %
confidence interval were presented. Non-Gaussian contin-
uous variables, such as LDL, triglycerides, CRP, indexed
LA volumes, mitral E-wave velocity, E/e’, and E/A, were
Fig. 1 Changes in left
ventricular global longitudinal
strain and septal e’ by group. An
improvement in GLS and septal
e’ can be seen in Groups 2 and
3. No improvement in these
parameters is noted in Group 1.
Estimates from a linear mixed
model. Data are presented as
estimated marginal mean and
95 % confidence interval.
Analysis adjusted for the
corresponding baseline variable,
changes in HbA1c and weight
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transformed as appropriate. Pairwise comparisons were
performed using Bonferroni correction. The Kruskal–
Wallis test was used to compare MRC dyspnea grade
between groups at baseline, and over time. A two-sided
p value\0.05 was considered significant. Statistical anal-
yses were performed using STATA v12 (STATA Corpo-
ration, Texas).
Results
Baseline clinical, metabolic, and echocardiographic
characteristics
The baseline clinical and metabolic characteristics of the
three groups of patients are summarized in Table 1. The
three groups of patients were comparable in all their clin-
ical and metabolic parameters except that Group 3 patients
were heaviest and had the highest body mass index (BMI).
Metabolic profiles were also comparable except Group 2
had the higher total cholesterol compared with Group 1. In
particular, there were no significant differences in the
baseline HbA1c between the three groups. Group 3 patients
had the highest, though nonsignificant, baseline CRP
levels. The median MRC dyspnea grade was 2 in all three
groups at baseline (p = 0.798). Medication use at baseline
is presented in Table 2.
The baseline echocardiographic characteristics are listed
in Table 3. The three groups had similar LV dimensions,
wall thickness, ejection fraction, and diastolic function
measured by the septal e’ velocities and diastolic function
grades. The LV anterior septal wall thickness was highest
in Group 3, but the LV mass indices were comparable.
Patients in Group 3 had the most impaired LV systolic
function as measured by LV GLS and strain rate. The cIB
of the LV anteroseptal wall was highest in Group 3. All
measures of LA function were similar across the three
groups at baseline.
Follow-up clinical and echocardiographic
characteristics
Table 1 shows the follow-up clinical and metabolic
characteristics of the three groups of patients. By study
design, the body weights, BMI, and HbA1c of patients in
Group 3 decreased significantly but that of Group 1
remained the same at 12 months. There was also an
increase in HDL-C, and a marginal decrease in triglyc-
erides in Group 3. There was a significant improvement in
MRC dyspnea grade from baseline to follow-up in Group
2 (grade 2 vs. grade 1, p = 0.0003) and Group 3 (grade 2
vs. grade 1, p = 0.001), but not Group 1 (grade 2 vs.
grade 2, p = 0.483).
Table 3 shows the follow-up echocardiographic char-
acteristics. By 12 months, there was a reduction in LV
anteroseptal wall thickness in Group 3 and a reduction in
LV end systolic volume leading to an increase in LV
ejection fraction in Groups 2 and 3. There was an increase
in septal e’ velocities (Fig. 1) and a reduction in septal E/e’
ratio in Groups 2 and 3. The E/e’ ratio in Group 1 actually
increased. There was a reduction in the LV anteroseptal
wall cIB in Group 3 only. There was a significant
improvement in LV GLS and strain rate in Groups 2 and 3
with the patients in Group 3 experiencing the larger
improvement (Fig. 1). The LV GLS was worst in Group 3
at baseline but was comparable between Groups 2 and 3 at
follow-up.
Inter- and intra-observer variability
Left ventricular GLS measurements were repeated in ten
randomly selected patients by the same observer (ML) on
the same echocardiographic images, and by a second
observer (DL) to determine intra-observer and inter-ob-
server variability, respectively. The intra-observer mean
differences for LV GLS were -0.19 ± 0.36 %
(r = 0.994). The inter-observer mean differences were
-0.33 ± 1.02 % (r = 0.94).
Discussion
The present study evaluated three groups of age-, gender-,
and baseline HbA1c-matched patients with type 2 diabetes
who had subclinical LV systolic and diastolic dysfunction.
They received intervention by diet and exercise advice,
anti-hyperglycaemic medications, and/or surgery. The
resultant improvement in glycaemic control led to signifi-
cant improvements in both systolic function (LV GLS and
ejection fraction) and diastolic function (e’). Furthermore,
weight loss in addition to improved glycaemic control
(Group 3) resulted in the largest improvements in LV
systolic and diastolic function, despite having worst func-
tion at baseline. Furthermore, there was a reduction in cIB
in this group reflecting a decrease in myocardial interstitial
fibrosis. Our study demonstrates the beneficial and additive
effects of improved glycaemic control and weight loss in
improving cardiac function in overweight patients with
type 2 diabetes.
Left ventricular systolic and diastolic function
in diabetes and impact of therapeutic intervention
The presence of LV dysfunction has been well described in
patients with type 2 diabetes independent of myocardial
ischaemia or hypertension [1–3]. We evaluated LV GLS
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Table 1 Baseline and follow-up clinical and metabolic characteristics in the three groups of patients
Characteristic Group 1: no weight loss ? worse
glycaemic control (n = 20)
Group 2: no weight loss ? improved
glycaemic control (n = 20)
Group 3: weight loss ? improved
glycaemic control (n = 10)
Body mass index (kg/m2)
Baseline 34.4 (31.2–37.5) 31.5 (28.3–34.7) 44.3 (39.8–48.7)§
Follow-up 35.7 (32.5–38.8) 32.5 (29.4–35.7)* 34.5 (30.0–40.0)*
Weight (kg)
Baseline 92.1 (82.1–102.0) 81.3 (71.3–91.2) 123.6 (109.5–137.7)§
Follow-up 94.2 (85.1–103.3)* 84.3 (75.2–93.4)* 95.7 (82.8–108.5)*
Waist circumference (cm)
Baseline 109 (102, 115) 103 (96, 109)§ 128 (119, 137)
Follow-up 111 (104, 117) 105 (99, 111) 114 (106, 122)*
Waist-to-hip ratio
Baseline 0.94 (0.91–0.98) 0.95 (0.91–0.99) 0.94 (0.89–0.99)
Follow-up 0.94 (0.91–0.96) 0.96 (0.93–0.99) 0.96 (0.92–1.00)
Systolic blood pressure (mmHg)
Baseline 137 (129–144) 133 (125–140) 128 (117–138)
Follow-up 134 (128–140) 129 (123–135) 131.4 (123–140)
Diastolic blood pressure (mmHg)
Baseline 78 (73–82) 73 (68–78) 74 (68–81)
Follow-up 81 (77–86) 77 (72–81) 79 (72–85)
HbA1c, NGSP (%) IFCC (mmol/mol)
Baseline 9.4 (8.6–10.2) 9.9 (9.1–10.7) 9.5 (8.4–10.6)
79 (70–88) 85 (76–93) 80 (68–92)
Follow-up 9.5 (8.7–10.3) 7.3 (6.5–8.1)* 6.7 (5.5–7.1)*
80 (72–89) 56 (48–65) 50 (37–54)
Total cholesterol (mg/dL)
Baseline 5.2 (4.7–5.7) 4.1 (3.5–4.6) 5.0 (4.3–5.8)
Follow-up 4.8 (4.3–5.4) 3.8 (3.2–4.3) 4.6 (3.9–5.4)
LDL cholesterol (mg/dL)
Baseline 2.7 (2.2–3.3) 1.8 (1.5–2.1) 2.6 (2.0–3.4)
Follow-up 2.3 (1.8–2.1) 1.8 (1.4–2.2) 2.5 (1.8–3.3)
HDL cholesterol (mg/dL)
Baseline 1.2 (1.1–1.4) 1.3 (1.2–1.4) 1.09 (0.9–1.3)
Follow-up 1.2 (1.1–1.3) 1.2 (1.1–1.3) 1.2 (1.1–1.4)*
Triglycerides (mg/dL)
Baseline 1.7 (1.4–2.2) 1.3 (1.1–1.6) 2.2 (1.5–3.2)
Follow-up 1.7 (1.4–2.2) 1.2 (1.0–1.5) 1.4 (1.1–1.9)
eGFR (mL/min/1.73 m2)
Baseline 91 (83–99) 92 (84–99) 89 (78–100)
Follow-up 101 (93–110) 84 (75–92) 96 (84–108)
C-reactive protein (mg/L)
Baseline 3.6 (2.2–5.9) 3.0 (1.8–5.1) 10.2 (5.2–19.8)
Follow-up 2.8 (1.8–4.4) 2.7 (1.7–4.4) 4.4 (2.3–8.4)
Estimates from a linear mixed model. Data are presented as estimated marginal means and 95 % confidence interval
NGSP National glycohaemoglobin standardization programme
Within groups: * p\ 0.05 for 1-year follow-up versus baseline
Between groups: § p\ 0.001 versus Group 2;  p\ 0.05 versus Group 1
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and e’ velocities in our patients as measures of LV systolic
and diastolic function, respectively. These measures have
proven advantages over LV ejection fraction and mitral E
and A velocities as measures of LV systolic and diastolic
function, respectively. In addition, both LV GLS and e’
velocities have incremental prognostic value over a wide
range of cardiovascular diseases [22, 28].
The underlying pathophysiologic mechanisms of dia-
betic cardiomyopathy are multifactorial and hypergly-
caemia plays a central role [6] Furthermore, patients with
type 2 diabetes are often obese and obesity per se has been
linked to LV dysfunction [29].
There is increasing evidence to suggest a link between
glycaemic control and LV function in diabetes. Studies
have suggested poor glycaemic control was associated with
LV diastolic dysfunction, manifest as either lower e’
velocities or raised LV filling pressure; and/or more
impaired LV systolic function with lower systolic strain
[2, 8, 9]. Furthermore, we have recently demonstrated that
improving glycaemic control in such patients resulted in
improvement in LV systolic and diastolic function [30].
The largest improvements in the aforementioned study
were seen in patients with the largest reduction in HbA1c
levels, and in those with the lowest HbA1c levels at the end
of the study. In contrast, patients who had worsened gly-
caemic control experienced further deterioration of LV
systolic function. However, studies examining the additive
effects of weight loss and improved glycaemic control on
LV function changes have been lacking.
Weight loss, however achieved, has been shown to
result in improved LV systolic and diastolic function [31].
In a study of 261 patients with BMI C 30 kg/m2 who
undertook a behavioural intervention programme including
dietary restriction and exercise training, independent pre-
dictors of improvement in LV function were weight
reduction, improvement in insulin resistance and absence
of diabetes [32]. There was no significant reduction in
HbA1c levels with intervention in either the adherent group
or in the non-adherent group; therefore, the effects of
improved glycaemic control on LV function was not
examined. Caloric restriction in obese patients with type 2
diabetes led to improved LV diastolic function [33]. The
severely obese patients have greater inflammatory burden
suggested by the significantly higher C-reactive protein
levels seen in patients in Group 3. While bariatric surgery
has proven benefits in weight reduction in obese patients
which leads to improvement in LV systolic and diastolic
function [34, 35], it is a different treatment approach to
dieting and exercise with additional impact on the neuro-
hormonal axis. Patients who have undergone sleeve gas-
trectomy have been found to have reduced ghrelin levels,
while the hindgut theory proposes that rapid delivery of
undigested nutrients to the hindgut following bariatric
surgery up-regulates production of glucagon-like peptide 1
and peptide-YY [36, 37]. How these neuro-hormonal
changes contribute to improvement in diabetic cardiomy-
opathy is unclear. In a study of severely obese patients,
beneficial effects of weight loss with bariatric surgery on
ECG abnormalities were seen more often in those who lost
weight and achieved normotension [38]. This supports the
importance of targeting multiple co-morbidities in these
patients to achieve desirable therapeutic goals.
Our study underlines the importance of both weight loss
and improving glycaemic control for the improvement of
Table 2 Baseline medications in the three groups of patients
Medication Group 1: no weight
loss ? worse glycaemic
control (n = 20)
Group 2: no weight
loss ? improved glycaemic
control (n = 20)
Group 3: weight
loss ? improved glycaemic
control (n = 10)
Aspirin or clopidogrel, n (%) 10 (25 %) 16 (40 %) 4 (20 %)
Angiotensin converting enzyme inhibitor
or angiotensin-II receptor blocker,
n (%)
32 (80 %) 26 (65 %) 16 (80 %)
Calcium channel blocker, n (%) 0 (0 %) 6 (15 %) 6 (30 %)
Beta-blocker, n (%) 2 (5 %) 4 (10 %) 0 (0 %)
Diuretic, n (%) 6 (15 %) 2 (5 %) 4 (20 %)
Spironolactone, n (%) 0 (0 %) 2 (5 %) 0 (0 %)
Statin, n (%) 28 (70 %) 26 (65 %) 10 (50 %)
Sulfonylurea, n (%) 6 (15 %) 20 (50 %) 6 (30 %)
Biguanide, n (%) 38 (95 %) 32 (80 %) 18 (90 %)
Di-peptidyl peptidase-4 inhibitor , n (%) 10 (26 %) 8 (20 %) 4 (20 %)
Insulin, n (%) 20 (50 %) 16 (40 %) 10 (50 %)
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Table 3 Baseline and follow-up echocardiographic characteristics in the three groups of patients
Characteristic Group 1: no weight loss ? worse
glycaemic control (n = 20)
Group 2: no weight loss ? improved
glycaemic control (n = 20)
Group 3: weight loss ? improved
glycaemic control (n = 10)
LV mass index (g/m2)
Baseline 78.9 (68.6–89.3) 93.5 (83.1–103.9) 90.1 (75.4–104.8)
Follow-up 83.3 (75.5–91.0) 89.2 (81.4–97.0) 75.6 (64.6–86.5)
LV end diastolic volume (mL)
Baseline 67 (58–80) 66 (54–78) 89 (72–106)
Follow-up 71 (60–82) 64 (53–76) 91 (75–107)
LV end systolic volume (mL)
Baseline 24 (18–31) 27 (20–34) 36 (26–45)
Follow-up 23 (18–27) 20 (15–24) 29 (22–35)
LVEF (%)
Baseline 65 (62–69) 61 (58–65) 60 (54–65)
Follow-up 69 (66–72) 70 (66–73)* 69 (64–73)*
E (cm/s)
Baseline 74 (67–83) 67 (61–75) 70 (61–82)
Follow-up 80 (72–88) 75 (68–82) 73 (64–83)
A (cm/s)
Baseline 87 (78–96) 72 (63–81) 82 (70–95)
Follow-up 88 (80–96) 73 (66–81) 80 (69–91)
E/A
Baseline 1.06 (0.98–1.13) 1.03 (0.95–1.10) 1.07 (0.96–1.18)
Follow-up 1.06 (0.99–1.12) 1.00 (0.93–1.07) 1.07 (0.97–1.17)
Septal s’ (cm/s)
Baseline 7.0 (6.4–7.6) 6.5 (5.9–8.1) 6.1 (5.3–6.9)
Follow-up 6.8 (6.3–7.3) 6.5 (6.0–7.0) 6.5 (5.7–7.3)
Septal e’ (cm/s)
Baseline 6.3 (5.8–6.7) 6.1 (5.6–6.6) 5.9 (5.2–6.6)
Follow-up 6.6 (5.7–7.4) 7.5 (6.6–8.3)* 8.2 (7.0–9.4)*
Septal a’ (cm/s)
Baseline 9.6 (8.5–10.6) 8.8 (7.7–9.8) 8.8 (7.3–10.3)
Follow-up 9.2 (8.3–10.1) 8.1 (7.2–9.0) 8.2 (7.0–9.4)
Septal E/e’
Baseline 11.9 (10.7–13.5) 11.1 (10–12.5) 11.9 (10.2–14.2)
Follow-up 12.3 (10.7–14.5) 10.2 (9.1–11.6) 9.0 (7.8–10.7)*
LA dimension (mm)
Baseline 35 (33, 38) 35 (33, 38) 39 (46, 42)
Follow-up 36 (34, 38) 33 (31, 35) 33 (30, 36)*
LA maximum volume indexed (mL/m2)
Baseline 26 (24–28) 28 (26–32) 28 (24–32)
Follow-up 27 (24–31) 28 (25–31) 30 (25–36)
LA active emptying volume indexed (mL/m2)
Baseline 10 (9–12) 10 (8–11) 9 (7–11)
Follow-up 10 (8–11) 10 (8–11) 12 (10–14)
LA passive emptying volume indexed (mL/m2)
Baseline 9 (8–11) 11 (9–13) 13 (11–15)
Follow-up 11 (9–14) 11 (9–13) 11 (8–14)
Anteroseptal wall cIB (dB)
Baseline -14.1 (-16.6 to 11.6) -10.6 (-13.1 to 8.1) -6.0 (-9.6 to 2.5)
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cardiac function in obese patients with type 2 diabetes. In
looking after subjects with type 2 diabetes, clinicians are
often faced with the task of managing their obesity as an
adjunct to improve their glycaemic control. Many therapies
for diabetes such as insulin and thiazolidinediones may
improve glycaemic control, but these agents can increase
the weight of patients. Poor glycaemic control and obesity
are both associated with worsening of LV function, and
targeting both parameters may have important and inde-
pendent effects in preventing the development of diabetic
cardiomyopathy. Given the current obesity epidemic and
prevalence of obesity and diabetic cardiomyopathy, these
results have important implications for preventing obesity
and diabetes-related morbidity and mortality.
Limitations
Our study was not a randomized trial. Such a study would
have been unethical. Given that the goal of our study was
to better understand the contributions of weight loss and
glycaemic improvement towards modulating LV function,
we used a group of patients with no weight loss and no
improvement in glycaemic control as a reference category,
and these patients may have been inherently different from
subjects in the other two groups. We did not have a group
of patients who achieved weight loss without any reduction
in HbA1c levels to examine the independent contribution
of weight loss alone without improved glycaemic control
on LV function. However, as the study by Kosmala et al.
has shown [32], improvement in LV function with weight
loss alone (their patients did not have significant reduction
in HbA1c with behavioural intervention) was less fre-
quently observed in patients with diabetes. We did not
evaluate changes in insulin resistance in our patients.
Weight loss in our Group 3 patients was achieved with
sleeve gastrectomy. The addition of a further group of
patients who were able to both improve glycaemic control
and lose weight by non-surgical means, and who are mat-
ched to group 1 and 2 for age, gender, BMI, and baseline
HbA1c would be ideal. Unfortunately, we do not have such
a group of patients in this study. This, together with the
high non-adherence rate in the Kosmala study, highlight
the significant challenges in achieving significant weight
loss in patients with type 2 diabetes and obesity, despite an
intensive and supervised multidisciplinary approach.
Finally, for patients who are only overweight or only
mildly obese, we cannot be certain whether weight loss by
diet and exercise alone and better glycaemic control confer
additive benefits.
Conclusions
In overweight patients with type 2 diabetes, weight loss and
improved glycaemic control had additive beneficial effects
on improving LV systolic and diastolic function.
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Table 3 continued
Characteristic Group 1: no weight loss ? worse
glycaemic control (n = 20)
Group 2: no weight loss ? improved
glycaemic control (n = 20)
Group 3: weight loss ? improved
glycaemic control (n = 10)
Follow-up -14.1 (-16.4 to 11.8) -12.5 (-14.8 to 10.2) -13.1 (-16.4 to 9.8)*
Posterior wall cIB (dB)
Baseline -16.5 (-19.0 to 14.1) -12.1 (-14.5 to 9.6) -11.7 (-15.2 to 8.3)
Follow-up -16.6 (-18.8 to 14.5) -15.3 (-17.4 to 13.2) -13.9 (-16.9 to 10.9)*
LV global longitudinal systolic strain (%)
Baseline -17.3 (-18.6 to 16.0) -15.3 (-16.6 to 14.0) -13.0 (-14.8 to 11.2)
Follow-up -17.9 (-19.0 to 16.8) -19.4 (-20.5 to 18.3)* -19.3 (-18.9 to 17.8)*
LV global longitudinal systolic strain rate (1/s)
Baseline -0.99 (-1.06 to 0.91) -0.82 (-0.89 to 0.74) -0.77 (-0.87 to 0.66)
Follow-up -0.98 (-1.05 to 0.91) -1.03 (-1.1 to 0.96)* -0.99 (-1.1 to 0.89)*
Estimates from a linear mixed model. Data are presented as estimated marginal means and 95 % confidence interval
Within groups: * p\ 0.05 for 1-year follow-up versus baseline
Between groups:  p\ 0.05 versus Group 1
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Informed consent All subjects had normal resting electrocardiogram
and provided written informed consent.
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